PKO BP BANKOWY Universal Pension Society JSC Acquires Shares of 138,802 Neurocrine Biosciences, Inc. $NBIX

PKO BP BANKOWY Universal Pension Society JSC acquired a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 138,802 shares of the company’s stock, valued at approximately $19,686,000. Neurocrine Biosciences comprises 9.9% of PKO BP BANKOWY Universal Pension Society JSC’s holdings, making the stock its 5th biggest position. PKO BP BANKOWY Universal Pension Society JSC owned approximately 0.14% of Neurocrine Biosciences as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in NBIX. USA Financial Formulas purchased a new stake in Neurocrine Biosciences in the fourth quarter valued at approximately $25,000. Geneos Wealth Management Inc. lifted its stake in Neurocrine Biosciences by 143.6% in the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after buying an additional 135 shares during the last quarter. Golden State Wealth Management LLC lifted its stake in Neurocrine Biosciences by 120.5% in the third quarter. Golden State Wealth Management LLC now owns 183 shares of the company’s stock valued at $26,000 after buying an additional 100 shares during the last quarter. Aster Capital Management DIFC Ltd purchased a new stake in Neurocrine Biosciences in the third quarter valued at approximately $49,000. Finally, Smartleaf Asset Management LLC lifted its stake in Neurocrine Biosciences by 112.0% in the third quarter. Smartleaf Asset Management LLC now owns 424 shares of the company’s stock valued at $59,000 after buying an additional 224 shares during the last quarter. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Insider Activity at Neurocrine Biosciences

In related news, Director Richard F. Pops sold 15,000 shares of the company’s stock in a transaction on Friday, May 15th. The stock was sold at an average price of $157.65, for a total transaction of $2,364,750.00. Following the transaction, the director owned 34,480 shares of the company’s stock, valued at $5,435,772. This represents a 30.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Leslie V. Norwalk sold 3,810 shares of the company’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $155.01, for a total value of $590,588.10. Following the transaction, the director directly owned 2,429 shares in the company, valued at $376,519.29. This represents a 61.07% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.60% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages have weighed in on NBIX. Truist Financial boosted their price objective on Neurocrine Biosciences from $140.00 to $155.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Leerink Partners upped their price target on Neurocrine Biosciences from $160.00 to $170.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 22nd. HC Wainwright upped their price target on Neurocrine Biosciences from $192.00 to $215.00 and gave the stock a “buy” rating in a research note on Tuesday, April 7th. Wedbush upped their price target on Neurocrine Biosciences from $166.00 to $176.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 6th. Finally, BMO Capital Markets cut their price target on Neurocrine Biosciences from $147.00 to $140.00 and set a “market perform” rating for the company in a research note on Thursday, February 12th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $184.15.

Neurocrine Biosciences Price Performance

Neurocrine Biosciences stock opened at $157.21 on Tuesday. Neurocrine Biosciences, Inc. has a 12 month low of $117.59 and a 12 month high of $162.39. The business has a 50 day simple moving average of $134.60 and a 200-day simple moving average of $138.45. The stock has a market capitalization of $15.81 billion, a PE ratio of 24.22, a price-to-earnings-growth ratio of 1.19 and a beta of 0.34.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research?driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.